Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Killer Cells, Natural | 8 | 2019 | 326 | 2.000 |
Why?
|
| Immunotherapy, Adoptive | 10 | 2024 | 789 | 1.580 |
Why?
|
| Dendritic Cells | 8 | 2011 | 409 | 1.340 |
Why?
|
| T-Lymphocytes | 6 | 2024 | 1678 | 0.870 |
Why?
|
| Cancer Vaccines | 6 | 2011 | 187 | 0.860 |
Why?
|
| CD40 Antigens | 3 | 2011 | 25 | 0.730 |
Why?
|
| Neoplasms | 6 | 2024 | 2751 | 0.680 |
Why?
|
| Antigens, CD19 | 2 | 2024 | 177 | 0.670 |
Why?
|
| Chemokine CCL5 | 2 | 2010 | 55 | 0.660 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2019 | 480 | 0.660 |
Why?
|
| Lymphoma, B-Cell | 1 | 2019 | 137 | 0.610 |
Why?
|
| Transduction, Genetic | 3 | 2016 | 298 | 0.590 |
Why?
|
| K562 Cells | 3 | 2019 | 95 | 0.580 |
Why?
|
| Cell Culture Techniques | 2 | 2016 | 288 | 0.560 |
Why?
|
| Cell Proliferation | 5 | 2024 | 2315 | 0.470 |
Why?
|
| Multiple Myeloma | 1 | 2015 | 170 | 0.420 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 803 | 0.400 |
Why?
|
| Oncolytic Viruses | 2 | 2009 | 71 | 0.380 |
Why?
|
| Interleukin-15 | 3 | 2024 | 95 | 0.360 |
Why?
|
| Adenoviridae | 5 | 2019 | 637 | 0.360 |
Why?
|
| Adjuvants, Immunologic | 2 | 2011 | 377 | 0.320 |
Why?
|
| Cell Movement | 2 | 2010 | 839 | 0.310 |
Why?
|
| Immunotherapy | 3 | 2010 | 661 | 0.310 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2007 | 144 | 0.270 |
Why?
|
| Genetic Vectors | 4 | 2019 | 973 | 0.270 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2009 | 401 | 0.260 |
Why?
|
| Flow Cytometry | 4 | 2017 | 810 | 0.260 |
Why?
|
| Genetic Therapy | 1 | 2010 | 707 | 0.250 |
Why?
|
| Lymphocyte Activation | 4 | 2017 | 681 | 0.250 |
Why?
|
| Receptors, CXCR4 | 1 | 2005 | 58 | 0.240 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2017 | 195 | 0.240 |
Why?
|
| Glypicans | 1 | 2024 | 39 | 0.240 |
Why?
|
| Blood Component Removal | 2 | 2016 | 32 | 0.230 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2023 | 1192 | 0.230 |
Why?
|
| Gangliosides | 1 | 2024 | 64 | 0.220 |
Why?
|
| Lymphoma, T-Cell | 1 | 2024 | 65 | 0.220 |
Why?
|
| RNA, Small Interfering | 1 | 2005 | 664 | 0.210 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 654 | 0.200 |
Why?
|
| Sarcoma | 1 | 2024 | 197 | 0.190 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2024 | 193 | 0.190 |
Why?
|
| Humans | 26 | 2024 | 122410 | 0.180 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 1679 | 0.180 |
Why?
|
| Receptor, ErbB-2 | 1 | 2024 | 496 | 0.180 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 155 | 0.180 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 815 | 0.180 |
Why?
|
| Glutamate Carboxypeptidase II | 2 | 2011 | 6 | 0.170 |
Why?
|
| Interleukin-12 | 3 | 2011 | 117 | 0.170 |
Why?
|
| Blotting, Western | 2 | 2015 | 1106 | 0.170 |
Why?
|
| Cell Transplantation | 2 | 2017 | 54 | 0.170 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 271 | 0.160 |
Why?
|
| Retroviridae | 1 | 2019 | 205 | 0.160 |
Why?
|
| Leukemia | 1 | 2022 | 375 | 0.160 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 48 | 0.150 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 1714 | 0.150 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 542 | 0.150 |
Why?
|
| Cell Line, Tumor | 5 | 2019 | 3299 | 0.150 |
Why?
|
| Cell Differentiation | 5 | 2017 | 1936 | 0.150 |
Why?
|
| Cell Survival | 2 | 2012 | 817 | 0.140 |
Why?
|
| CD3 Complex | 1 | 2017 | 84 | 0.140 |
Why?
|
| Cytokines | 3 | 2024 | 1288 | 0.140 |
Why?
|
| Lipopolysaccharides | 2 | 2010 | 292 | 0.140 |
Why?
|
| CD28 Antigens | 1 | 2017 | 78 | 0.140 |
Why?
|
| Herpesvirus 4, Human | 1 | 2019 | 663 | 0.130 |
Why?
|
| Feeder Cells | 1 | 2016 | 9 | 0.130 |
Why?
|
| Mice | 9 | 2019 | 17628 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 2 | 2009 | 1009 | 0.130 |
Why?
|
| Animals | 11 | 2019 | 33888 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1119 | 0.120 |
Why?
|
| Antigen-Presenting Cells | 1 | 2014 | 119 | 0.110 |
Why?
|
| Organic Chemicals | 2 | 2011 | 59 | 0.110 |
Why?
|
| Down-Regulation | 2 | 2006 | 701 | 0.110 |
Why?
|
| 4-1BB Ligand | 1 | 2012 | 11 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 2480 | 0.100 |
Why?
|
| Cryopreservation | 1 | 2012 | 82 | 0.100 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2012 | 98 | 0.100 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2019 | 263 | 0.100 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 13 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2011 | 9 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 532 | 0.100 |
Why?
|
| Aptamers, Nucleotide | 1 | 2011 | 24 | 0.100 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2011 | 9 | 0.090 |
Why?
|
| Female | 10 | 2024 | 64958 | 0.090 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2011 | 83 | 0.090 |
Why?
|
| Transplantation, Heterologous | 2 | 2014 | 257 | 0.090 |
Why?
|
| Young Adult | 2 | 2024 | 8805 | 0.090 |
Why?
|
| Tumor Escape | 1 | 2010 | 62 | 0.090 |
Why?
|
| Chemotaxis | 1 | 2010 | 55 | 0.080 |
Why?
|
| Adenovirus E1B Proteins | 1 | 2009 | 3 | 0.080 |
Why?
|
| beta-Defensins | 1 | 2009 | 12 | 0.080 |
Why?
|
| Mice, SCID | 2 | 2014 | 572 | 0.080 |
Why?
|
| COS Cells | 1 | 2009 | 273 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 4 | 2011 | 4385 | 0.080 |
Why?
|
| Aged | 4 | 2024 | 18781 | 0.080 |
Why?
|
| Child | 4 | 2024 | 24118 | 0.080 |
Why?
|
| Computer Simulation | 1 | 2011 | 609 | 0.080 |
Why?
|
| Ovalbumin | 1 | 2009 | 318 | 0.080 |
Why?
|
| Models, Molecular | 1 | 2011 | 1069 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2024 | 13840 | 0.080 |
Why?
|
| Receptors, CCR7 | 1 | 2007 | 21 | 0.070 |
Why?
|
| Oncolytic Virotherapy | 1 | 2009 | 83 | 0.070 |
Why?
|
| Cell Line | 2 | 2011 | 2785 | 0.070 |
Why?
|
| Antigens, Surface | 1 | 2007 | 123 | 0.070 |
Why?
|
| Middle Aged | 4 | 2024 | 25591 | 0.070 |
Why?
|
| Cell Polarity | 1 | 2007 | 125 | 0.070 |
Why?
|
| Th1 Cells | 1 | 2007 | 152 | 0.070 |
Why?
|
| Interleukin-2 | 2 | 2017 | 237 | 0.070 |
Why?
|
| Interferon-gamma | 1 | 2009 | 513 | 0.070 |
Why?
|
| Male | 7 | 2024 | 59592 | 0.060 |
Why?
|
| Adolescent | 2 | 2024 | 18984 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2007 | 394 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2017 | 333 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2024 | 12036 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2006 | 343 | 0.060 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2007 | 506 | 0.060 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 20 | 0.060 |
Why?
|
| Vidarabine | 1 | 2024 | 79 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2005 | 236 | 0.060 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 122 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2005 | 321 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 493 | 0.060 |
Why?
|
| Neoplasm Grading | 1 | 2024 | 267 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2005 | 1076 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2005 | 608 | 0.050 |
Why?
|
| Adult | 4 | 2024 | 28746 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2011 | 4511 | 0.050 |
Why?
|
| Centrifugation | 1 | 2022 | 26 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2024 | 422 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 404 | 0.050 |
Why?
|
| Toll-Like Receptors | 2 | 2011 | 83 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 326 | 0.050 |
Why?
|
| Risk Factors | 1 | 2015 | 9871 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2022 | 659 | 0.040 |
Why?
|
| Phenotype | 1 | 2010 | 4218 | 0.040 |
Why?
|
| Apoptosis | 1 | 2006 | 1795 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 1166 | 0.040 |
Why?
|
| Glioma | 1 | 2024 | 495 | 0.040 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2019 | 20 | 0.040 |
Why?
|
| Disease Progression | 1 | 2005 | 1994 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2011 | 462 | 0.040 |
Why?
|
| Chemokines | 1 | 2019 | 137 | 0.040 |
Why?
|
| Recurrence | 1 | 2022 | 1412 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2011 | 3776 | 0.040 |
Why?
|
| Lymphoma | 2 | 2014 | 323 | 0.040 |
Why?
|
| Ligands | 1 | 2019 | 534 | 0.040 |
Why?
|
| Interleukin-7 | 1 | 2017 | 43 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2005 | 1890 | 0.040 |
Why?
|
| Leukocyte Common Antigens | 1 | 2017 | 91 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 873 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2019 | 773 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 4649 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 547 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2014 | 58 | 0.030 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2014 | 60 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 172 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2014 | 108 | 0.030 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2014 | 58 | 0.030 |
Why?
|
| Viral Matrix Proteins | 1 | 2014 | 109 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2019 | 511 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2014 | 125 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 286 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 5974 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 4987 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 2014 | 441 | 0.030 |
Why?
|
| Enzyme Assays | 1 | 2011 | 12 | 0.020 |
Why?
|
| Surface Plasmon Resonance | 1 | 2011 | 45 | 0.020 |
Why?
|
| Carcinoma | 1 | 2014 | 282 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 394 | 0.020 |
Why?
|
| Antigens, Nuclear | 1 | 2011 | 62 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 2011 | 29 | 0.020 |
Why?
|
| Tacrolimus Binding Protein 1A | 1 | 2011 | 20 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2011 | 184 | 0.020 |
Why?
|
| Protein Engineering | 1 | 2011 | 73 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2011 | 107 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2011 | 233 | 0.020 |
Why?
|
| Peptides | 1 | 2014 | 801 | 0.020 |
Why?
|
| Drug Design | 1 | 2011 | 147 | 0.020 |
Why?
|
| Protein Transport | 1 | 2011 | 369 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2011 | 565 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 215 | 0.020 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2011 | 215 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 483 | 0.020 |
Why?
|
| Infant | 1 | 2024 | 12347 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 742 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 1402 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 1736 | 0.020 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2006 | 12 | 0.020 |
Why?
|
| Biosynthetic Pathways | 1 | 2006 | 24 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 6303 | 0.020 |
Why?
|
| Mitochondrial Proteins | 1 | 2006 | 238 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 2441 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 3076 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 15879 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 1516 | 0.010 |
Why?
|
| Melanoma | 1 | 2006 | 836 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 801 | 0.010 |
Why?
|